Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.
modified citrus pectin
non-metastatic biochemically relapsed prostate cancer
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
11 Aug 2023
11 Aug 2023
Historique:
received:
02
07
2023
revised:
03
08
2023
accepted:
08
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol
Identifiants
pubmed: 37630724
pii: nu15163533
doi: 10.3390/nu15163533
pmc: PMC10459199
pii:
doi:
Substances chimiques
citrus pectin
47EQO8LE7H
Pectins
89NA02M4RX
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : EcoNugenics Inc., Santa Rosa, CA, USA.
ID : N/A
Références
Cancer Res. 2010 Oct 1;70(19):7476-88
pubmed: 20719885
Prostate Cancer Prostatic Dis. 2015 Mar;18(1):49-55
pubmed: 25384338
Front Oncol. 2019 Sep 11;9:884
pubmed: 31572678
Trends Cancer. 2020 Aug;6(8):702-715
pubmed: 32534790
Nutrients. 2014 Dec 22;6(12):6020-47
pubmed: 25533011
Prostate Cancer Prostatic Dis. 2013 Mar;16(1):50-5
pubmed: 22689129
BJU Int. 2011 Sep;108(6):806-13
pubmed: 21884356
J Urol. 2007 Feb;177(2):540-5
pubmed: 17222629
Curr Opin Immunol. 2017 Apr;45:8-15
pubmed: 28088061
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Nutrients. 2019 Jun 29;11(7):
pubmed: 31261861
Cells. 2020 Feb 18;9(2):
pubmed: 32085497
J Urol. 2008 Jun;179(6):2181-5; discussion 2185-6
pubmed: 18423743
Eur Urol. 2019 Jun;75(6):967-987
pubmed: 30342843
Hematol Oncol Clin North Am. 2013 Dec;27(6):1205-19, viii
pubmed: 24188259
Nutrients. 2021 Nov 28;13(12):
pubmed: 34959847
Med Clin North Am. 2018 Mar;102(2):199-214
pubmed: 29406053
Int J Cancer. 2018 Feb 15;142(4):741-746
pubmed: 29023685
Bioorg Chem. 2023 Jan;130:106230
pubmed: 36375352
Integr Cancer Ther. 2010 Jun;9(2):197-203
pubmed: 20462856
Nat Rev Drug Discov. 2023 Apr;22(4):295-316
pubmed: 36759557
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Eur Urol. 2023 Mar;83(3):267-293
pubmed: 36494221
Clin Cancer Res. 2005 Jun 15;11(12):4437-43
pubmed: 15958628
J Clin Oncol. 2005 Feb 1;23(4):826-31
pubmed: 15681527
J Exp Med. 2020 Feb 3;217(2):
pubmed: 31873723
Front Public Health. 2022 Feb 16;10:811044
pubmed: 35252092
J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83
pubmed: 13130113
J Biol Chem. 2016 Jun 17;291(25):13318-34
pubmed: 27129206
Eur Urol. 2014 Feb;65(2):467-79
pubmed: 24321502
J Natl Cancer Inst. 1995 Mar 1;87(5):348-53
pubmed: 7853416
Cold Spring Harb Perspect Med. 2017 Sep 1;7(9):
pubmed: 28389515
Cancer. 2020 Jan 1;126(9):1969-1978
pubmed: 32012233
Eur Urol Oncol. 2021 Dec;4(6):877-892
pubmed: 34716119
Neoplasia. 2012 Jan;14(1):65-73
pubmed: 22355275
JAMA. 1999 May 5;281(17):1591-7
pubmed: 10235151
BJU Int. 2012 Jan;109(1):32-9
pubmed: 21777360
Clin Cancer Res. 2006 Jul 1;12(13):4018-26
pubmed: 16818701
Prostate Cancer Prostatic Dis. 2003;6(4):301-4
pubmed: 14663471
J Urol. 1974 Jan;111(1):58-64
pubmed: 4813554
Expert Rev Mol Med. 2008 Jun 13;10:e17
pubmed: 18549522
Clin Adv Hematol Oncol. 2013 Jan;11(1):14-23
pubmed: 23416859
Cancer Lett. 2012 Dec 1;325(1):54-62
pubmed: 22659736
J Clin Oncol. 2005 Oct 1;23(28):6992-8
pubmed: 16192586
Toxicology. 2013 Jan 7;303:139-46
pubmed: 23146760
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-8
pubmed: 35503984
JAMA. 2005 Jul 27;294(4):433-9
pubmed: 16046649
J Clin Oncol. 2006 Sep 20;24(27):4448-56
pubmed: 16983113
Int J Mol Med. 2018 Feb;41(2):599-614
pubmed: 29207027
J Natl Cancer Inst. 2002 Dec 18;94(24):1854-62
pubmed: 12488479
Clin Cancer Res. 2010 Nov 1;16(21):5269-76
pubmed: 20978144
Biochem Mol Biol Int. 1995 Nov;37(5):833-41
pubmed: 8624488